Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 08:30 ET | Source: Pluri Inc.

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple...
February 18, 2026 08:00 ET | Source: Pluri Inc.

Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using...
January 22, 2026 09:15 ET | Source: Pluri Inc.

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based...
December 22, 2025 07:00 ET | Source: Pluri Inc.

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for...